Sabrina Newman

Sabrina Newman

Auto-generated profile, based on publicly available information

Sabrina Newman

Department of Dermatology, University of Colorado School of Medicine, Department of Dermatology, Aurora, CO, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in JMIR Dermatology
Verified
Journal Article
Open access
SZSophia Zita
Sophia Zita
LBLindsey Broussard
Lindsey Broussard
JHJeremy Hugh
Jeremy Hugh
SNSabrina Newman
Sabrina Newman
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, life-threatening reaction to a culprit drug that frequently involves end-organ damage. Corticosteroids are the first-line treatment for DRESS syndrome; however, corticosteroids may be contraindicated in certain patient populations. There are currently only 54 cases detailing the use of cyclosporine for the treatment of DRESS syndrome reported in the literature. Objective: The aim of this case series was to examine the treatment of DRESS syndrome with cyclosporine in a large patient cohort by aggregating time to symptom resolution, recurrence rate, and treatment dose and duration. Methods: This study was a retrospective cohort study. Patients diagnosed with DRESS syndrome by a board-certified dermatologist and treated at the University of Colorado Hospital from 2015 to 2019 were included. Results: Our inclusion criterion was met by 19 occurrences of DRESS syndrome. With a short course of cyclosporine, 17 of 19 patients in our cohort (89%) had resolution of symptoms (mean treatment length of 5.26 days). DRESS syndrome’s relapse after treatment with cyclosporine occurred in 3 of 19 (16%) occurrences of the cohort. Conclusions: Our study supports the use of cyclosporine in the treatment of DRESS syndrome, particularly in patients who are unable to sustain prolonged immunosuppression. Further research is necessary to compare the efficacy of cyclosporine to the current standard of care in a larger study population and investigate long-term outcomes.

18 November 2025 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
DHDakota Hitchcock
Dakota Hitchcock
SNSabrina Newman
Sabrina Newman
CPChanglee S. Pang
Changlee S. Pang
SRShyam Raghavan
Shyam Raghavan

24 July 2022 in JMIR Preprints
Verified
Preprint
Open access
SZSophia Zita
Sophia Zita
LBLindsey Broussard
Lindsey Broussard
JHJeremy Hugh
Jeremy Hugh
SNSabrina Newman
Sabrina Newman
BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, life-threatening reaction to a culprit drug that frequently involves end-organ damage. Corticosteroids are the first-line treatment for DRESS syndrome; however, corticosteroids may be contraindicated in certain patient populations. There are currently only 54 cases detailing the use of cyclosporine for the treatment of DRESS syndrome reported in the literature. OBJECTIVE The aim of this case series was to examine the treatment of DRESS syndrome with cyclosporine in a large patient cohort by aggregating time to symptom resolution, recurrence rate, and treatment dose and duration. METHODS This study was a retrospective cohort study. Patients diagnosed with DRESS syndrome by a board-certified dermatologist and treated at the University of Colorado Hospital from 2015 to 2019 were included. RESULTS Our inclusion criterion was met by 19 occurrences of DRESS syndrome. With a short course of cyclosporine, 17 of 19 patients in our cohort (89%) had resolution of symptoms (mean treatment length of 5.26 days). DRESS syndrome’s relapse after treatment with cyclosporine occurred in 3 of 19 (16%) occurrences of the cohort. CONCLUSIONS Our study supports the use of cyclosporine in the treatment of DRESS syndrome, particularly in patients who are unable to sustain prolonged immunosuppression. Further research is necessary to compare the efficacy of cyclosporine to the current standard of care in a larger study population and investigate long-term outcomes. CLINICALTRIAL

30 January 2026 in JMIR Dermatology
Verified
Journal Article
Open access
DHDakota Hitchcock
Dakota Hitchcock
SNSabrina Newman
Sabrina Newman
In this analysis of dermatology e-consults at a large academic health system, advanced practice providers had nearly threefold higher conversion rates to in-person visits compared to board-certified dermatologists, with potential implications for access and resource utilization.